On Friday, Alnylam Pharmaceuticals received an upgrade to its Relative Strength (RS) Rating, from 89 to 93.
Here Are 3 Keys For Successful Stock Investing
IBD's proprietary RS Rating identifies technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating as they launch their largest runs.
The IBD 50 stock is now considered extended and out of buy range after clearing a 304.39 buy point in a first-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Alnylam Pharmaceuticals showed -43% EPS growth last quarter, while sales growth came in at 17%.
Alnylam Pharmaceuticals holds the No. 83 rank among its peers in the Medical-Biomed/Biotech industry group. Incyte, Halozyme Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
